MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
MorphoSys AG /
MorphoSys Strengthens Clinical Development Organization with Three Management
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that it has completed the expansion of its senior clinical development
team by appointing Dr. Gabriele Elbl as Head of Regulatory Affairs, Dr. Ludger
Langer as Head of Clinical Operations and Project Management and most recently
Dr. Steffen Heeger as Head of Clinical Research.
Gabriele Elbl joined MorphoSys after working for more than 20 years in small and
large pharmaceutical companies. During this time she gained a deep understanding
of all regulatory aspects of product development, both for the US and the EU.
Dr. Elbl has extensive experience of development programs for biologics through
interactions with both the American Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). Most recently she held the position of Senior
Vice President, Regulatory Affairs at Wilex AG, Munich. Prior to that she worked
as a Scientific Administrator at the EMA, London, and served as Head of
Pharmaceutical Department at Sanofi Winthrop in Munich. Dr. Elbl studied
pharmacy and received a PhD in Pharmaceutical Biology from the Ludwig-
Ludger Langer joined MorphoSys from PRA International. He brings almost 20 years
of clinical operations and project management experience to MorphoSys. Dr.
Langer held several positions of increasing seniority in Clinical Operations and
Project Management with a focus on planning and execution of multiregional
clinical trials. Prior to joining MorphoSys, Dr. Langer was Vice President,
Clinical Operations, Europe, Asia-Pacific and Africa at PRA International. Dr.
Langer studied pharmacy and received a PhD from the Goethe University,
Steffen Heeger is an oncologist with deep experience in oncology drug
development from his past ten years at Merck Serono, where he was Head of
Medical Affairs and where he led the Global Clinical Development Team for
Erbitux(Â®). Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and
continued his medical training at the Clinic of Hematology/Oncology of the
University of Heidelberg. During this time he was also a scientist at the German
Cancer Research Center (DKFZ) in Heidelberg where he worked on the development
of antibody conjugates. He received a PhD in Medicine from the University of
"We are very pleased to have gained three outstanding individuals for these key
positions within the MorphoSys development organization," explained Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG. "The appointment of
Gabriele Elbl and Ludger Langer earlier this year and most recently Steffen
Heeger already had a significant impact on our development capabilities and
underscores our strong commitment to the further expansion, development and
commercialization of our proprietary drug portfolio."
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(Â®), HuCAL GOLD(Â®), HuCAL PLATINUM(Â®), CysDisplay(Â®), RapMAT(Â®), arYla(Â®)
and Ylanthia(Â®) and 100 billion high potentials(Â®) are registered trademarks of
Slonomics(Â®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-LÃ¶ser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire